An Observational Study Investigating the Effectiveness of Pravastatin on Renal Function in Korean Dyslipidemic Patients With Type 2 Diabetes

NCT ID: NCT05107063

Last Updated: 2021-11-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

2972 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-01-20

Study Completion Date

2018-04-19

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study investigated the effectiveness of pravastatin on renal function in Korean dyslipidemic patients with Type 2 diabetes.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This survey study investigated the effect of routine initiation single dose of pravastatin (10 mg, 20 mg, or 40 mg) on renal function in Korean dyslipidemic patients with Type 2 diabetes. The study also examined the effect of pravastatin on lipid profiles, glucose metabolism, and safety.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dyslipidemia Associated With Type II Diabetes Mellitus

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Dyslipidemia Type II Diabetes Mellitus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Dyslipidemic participants with Type 2 diabetes

Dyslipidemic participants with Type 2 diabetes who received a routine initiation dose of pravastatin 10 mg, 20 mg or 40 mg single dose once daily and maintained a low cholesterol diet throughout the study period.

Pravastatin

Intervention Type DRUG

Routine initiation dose was 10 mg, 20 mg or 40 mg single dose once daily. Depending on patient response, dose could have been increased up to 40 mg. Maintenance dose was 10-40 mg once daily.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pravastatin

Routine initiation dose was 10 mg, 20 mg or 40 mg single dose once daily. Depending on patient response, dose could have been increased up to 40 mg. Maintenance dose was 10-40 mg once daily.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participants with Type 2 diabetes (currently using an antidiabetic drug or satisfying diagnostic criteria of diabetes as defined by American Diabetes Association)
* Participants with dyslipidemia (currently using an antidyslipidemic drug or satisfying the Health Insurance Review \& Assessment Service insurance coverage treatment criteria\*) for whom drug treatment with pravastatin is confirmed
* Participants determined to be eligible as subjects at the discretion of the investigator
* Participants who voluntarily provided written consent using the Informed Consent Form on Use of Information

Exclusion Criteria

* Participants who had administered pravastatin prior to study participation
* Participants with hypersensitivity to the investigational product or its history
* Participants with an active liver disease or persistent elevation of transaminase with an unknown cause
* Pregnant woman or women with childbearing potential, breastfeeding mothers
* Children
* Participants with severe hepatic or renal insufficiency
* Participants with myopathy
* Participants with cholestasis
* Participants with hypercholesterolemia due to hyperalphalipoproteinemia accompanied by HDL cholesterol elevation
* Participants with a genetic problem such as galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Daiichi Sankyo Korea Co., Ltd.

INDUSTRY

Sponsor Role collaborator

Daiichi Sankyo

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Global Clinical Leader

Role: STUDY_DIRECTOR

Daiichi Sankyo

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Korea University Ansan Hospital

Ansan, , South Korea

Site Status

The Catholic University of Korea, Bucheon St. Mary's Hospital

Bucheon-si, , South Korea

Site Status

Yeongnam University Medical Center

Busan, , South Korea

Site Status

Inje University Busan Paik Hospital - Site 23

Busan, , South Korea

Site Status

Inje University Busan Paik Hospital - Site 26

Busan, , South Korea

Site Status

Bong Seng Memorial Hospital

Busan, , South Korea

Site Status

Pusan National University Hospital - Site 43

Busan, , South Korea

Site Status

Pusan National University Hospital - Site 49

Busan, , South Korea

Site Status

Kosin University Gospel Hospital

Busan, , South Korea

Site Status

Changwon Fatima Hospital

Changwon, , South Korea

Site Status

Soon Chun Hyang University Cheonan Hospital

Cheonan, , South Korea

Site Status

Daegu Catholic University Medical Center

Daegu, , South Korea

Site Status

Eulji University DaeJeon Medical Center

Daejeon, , South Korea

Site Status

Konyang University Hospital

Daejeon, , South Korea

Site Status

GangNeung Asan Hospital

Gangneung, , South Korea

Site Status

Dongguk University Ilsan Hospital

Goyang, , South Korea

Site Status

Inje University Ilsan Paik Hospital

Goyang, , South Korea

Site Status

National Health Insurance Service Ilsan Hospital

Goyang, , South Korea

Site Status

Myongji Hospital

Goyang, , South Korea

Site Status

Chosun University Hospital

Gwangju, , South Korea

Site Status

Gwangju Veterans Hospital

Gwangju, , South Korea

Site Status

Gachon University Gil Medical Center

Incheon, , South Korea

Site Status

Bundang CHA General Hospital

Seongnam, , South Korea

Site Status

Seoul National University Bundang Hospital

Seongnam, , South Korea

Site Status

HANIL General Hospital

Seoul, , South Korea

Site Status

Korea Cancer Center Hospital

Seoul, , South Korea

Site Status

Eulji University Medical Center - Site 20

Seoul, , South Korea

Site Status

Eulji University Medical Center - Site 52

Seoul, , South Korea

Site Status

Seoul Medical Center

Seoul, , South Korea

Site Status

The Catholic University of Korea, St. Paul's Hospital

Seoul, , South Korea

Site Status

Yonsei University Health System, Severance Hospital

Seoul, , South Korea

Site Status

Soon Chun Hyang University Seoul Hospital

Seoul, , South Korea

Site Status

Kyung Hee University Hospital at Gangdong

Seoul, , South Korea

Site Status

Kangdong Sacred Heart Hospital

Seoul, , South Korea

Site Status

VHS Medical Center

Seoul, , South Korea

Site Status

Yonsei University Health System, Gangnam Severance Hospital

Seoul, , South Korea

Site Status

Samsung Medical Center

Seoul, , South Korea

Site Status

Chung-Ang Univerisity Hospital

Seoul, , South Korea

Site Status

The Catholic University of Korea, Yeouido St. Mary's Hospital

Seoul, , South Korea

Site Status

St. Carollo General Hospital

Suncheon, , South Korea

Site Status

The Catholic University of Korea, St. Vincent's Hospital - Site 45

Suwon, , South Korea

Site Status

The Catholic University of Korea, St. Vincent's Hospital - Site 50

Suwon, , South Korea

Site Status

Ajou University Hospital - Site 04

Suwon, , South Korea

Site Status

Ajou University Hospital - Site 05

Suwon, , South Korea

Site Status

Dongkang Medical Center

Ulsan, , South Korea

Site Status

Yonsei University, Wonju Severance Christian Hospital - Site 10

Wŏnju, , South Korea

Site Status

Yonsei University, Wonju Severance Christian Hospital - Site 15

Wŏnju, , South Korea

Site Status

Countries

Review the countries where the study has at least one active or historical site.

South Korea

References

Explore related publications, articles, or registry entries linked to this study.

Kim HJ, Hur KY, Lee YH, Kim JT, Lee YK, Baek KH, Choi EJ, Hwang WM, Bang KT, Lim JS, Chung YJ, Jo SR, Oh JS, Lee SH, Ko SH, Choi SH. Effect of Pravastatin on Kidney Function in Patients with Dyslipidemia and Type 2 Diabetes Mellitus: A Multicenter Prospective Observational Study. Adv Ther. 2024 Aug;41(8):3119-3137. doi: 10.1007/s12325-024-02862-5. Epub 2024 Jun 16.

Reference Type DERIVED
PMID: 38880822 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MVT-OS-15-01

Identifier Type: -

Identifier Source: org_study_id